Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.


June 29, 2020 — A type of smart magnetic resonance imaging (MRI) scan used in people with heart disease could help assess whether children's cancers are especially aggressive and spot early signs that targeted treatments are working, a new study suggests.

Researchers showed that the MRI imaging technique, known as T1-mapping, could offer crucial insights into the biology of childhood cancers and give an early warning of how effective targeted treatments were likely to be.

T1 mapping scans measure how water molecules interact at a microscopic level inside cells to understand the cellular make-up of tissue, and are used in heart disease to assess damage to heart muscle tissue.

Now scientists at The Institute of Cancer Research, London, have shown that the non-invasive scanning technique has the potential to pick out children with high-risk forms of neuroblastoma, a type of childhood tumour.

The researchers believe T1 mapping scans could improve the use of precision medicine in children with neuroblastoma and potentially in cancer patients more widely, by ensuring treatments are tailored for each patient, and rapidly stopped when they are not working.

The study was published in the journal Cancer Research and funded by Children with Cancer UK, Cancer Research UK and The Rosetrees Trust.

Researchers studied T1 mapping in mice with an aggressive form of neuroblastoma to get a clear picture of the microscopic and physical characteristics of the tumour.

The team at The Institute of Cancer Research (ICR) used artificial intelligence to map the different cell populations in tumours and compared these maps with those created using non-invasive T1 mapping MRI scans.

The researchers found that regions with high T1 values - where water molecules can behave 'more freely' - corresponded to hotspots of more aggressive cancer cells, which spread and grow faster. Meanwhile, areas with low T1 values corresponded to more benign or dead tissue, which is less harmful.

The researchers also looked at whether the imaging technique could help assess how mice with neuroblastoma would respond to two targeted drugs, alisertib and vistusertib, which target MYCN, a key protein linked to aggressive forms of the disease.

They found that when alisertib and vistusertib successfully stopped the growth of tumours in mice, there was a decrease in T1 measures - reflecting the death of aggressive cancer cells. This suggests T1 measures could be used as a biomarker - a measurable indicator which can guide treatment by indicating whether a drug is working or not.

The researchers believe aggressive cancer cells have high T1 values because they tend to be small, but have large nuclei - the control centres within each cell containing our DNA, near which water can behave 'more freely'.

By evaluating tumours' cellular make-up with T1 MRI scans, clinicians would be able to get an accurate understanding of the stage and aggressiveness of the disease in children with neuroblastoma.

Next, researchers at the ICR - a charity and research institute - plan to assess the clinical benefit of T1 mapping as part of a clinical study involving children.

The new research is the first to assess the benefit of the MRI technique as a 'smart' cancer biopsy - and researchers believe the results could be replicated more widely in other cancer types in children and adults.

Study leader Yann Jamin, M.D., Children with Cancer UK Research Fellow at The Institute of Cancer Research, London, said: "Our findings show that an imaging technique readily available on most MRI scanners has the potential to pick out children with aggressive cancer and give us early signs of whether a treatment is working. We've shown in mice that this technique can give us detailed insights into the biology of neuroblastoma tumours and help guide use of precision medicine, and next we want to assess its effectiveness in children with cancer.

"It is easy to perform and analyse T1 MRI scans, and they could be used to provide insights into many aspects of cancer biology - and help doctors to design tailored treatments based on how aggressive a tumour appears to be."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: "It's exciting that we've shown that a scan widely used to image the heart has the potential to greatly improve our understanding and treatment of cancer too. There is already a lot of experience in using this technique in NHS hospitals, and I hope we can rapidly move to assessing its use in clinical trials of cancer patients.

"It's vital that we find ways to improve treatments for aggressive childhood cancers like neuroblastoma - and also that we spare children unnecessary side effects by minimising exposure to drugs that do not seem to be working."

Mark Brider, Chief Executive Officer, Children with Cancer UK said: "Neuroblastoma is one of the most common childhood tumours with around 100 children, mostly under five years old, diagnosed every year in the UK. Yet it also has one of the lowest survival rates and in its high-risk form is one of the most difficult childhood cancers to cure.

"It is crucial that we find more effective and personalised treatments for children with neuroblastoma. The findings of Dr. Jamin and his team represent an important step towards the development of new and kinder treatments that reduce the burden of toxicity for young cancer patients and improve survival rates in this aggressive and hard-to-treat cancer."

For more information: www.icr.ac.uk


Related Content

News | Radiation Therapy

May 23, 2024 — RaySearch Laboratories AB and C-RAD announced a collaboration agreement, aiming at jointly developing ...

Time May 23, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, recently ...

Time May 22, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 21, 2024 — RaySearch Laboratories AB announced that the oncology information system RayCare* 2024A has been ...

Time May 21, 2024
arrow
News | Proton Therapy

May 21, 2024 — IBA, a world leader in particle accelerator technology, announced that it has signed a contract with the ...

Time May 21, 2024
arrow
News | Radiology Business

May 20, 2024 — Associated Medical Professionals of NY (A.M.P.) announced that internationally recognized radiation ...

Time May 20, 2024
arrow
News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Radiation Therapy

May 16, 2024 — Today marks a significant milestone in cancer care with the introduction of bipartisan federal ...

Time May 16, 2024
arrow
News | Artificial Intelligence

May 15, 2024 — Heart disease is the leading cause of mortality in the U.S., accounting for one out of every five deaths ...

Time May 15, 2024
arrow
News | FDA

May 14, 2024 — Indica Labs, the leading provider of digital pathology solutions, announced today that it received FDA ...

Time May 14, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
Subscribe Now